## Please add the following new claims:



34. (New) The composition according to Claim 26, wherein the immune systemic response is a systemic B and T cell response specific to said peptide and wherein the immune systemic response is stronger than immune systemic response induced when said peptide is administered by parenteral route.

35. (New) The composition according to Claim 26, wherein the mucosal route is intranasal route.

36. (New) The composition according to Claim 26, wherein the mucosal route is sublingual route.

37. (New) The composition according to Claim 26, wherein said immune response induces a mucosal protection in vivo against a malaria infection.

38. (New) The composition according to Claim 30, wherein the mucosal route is intranasal route.

39. (New) The composition according to Claim 30, wherein the mucosal route is sublingual route.

40. (New) The composition according to Claim 30, wherein said immune response induces a mucosal protection in vivo against a malaria infection.

## **BASIS FOR THE AMENDMENT**

Claims 26 and 30 have been amended.

Claims 34-40 have been added.

The amendment of Claims 26 and 30 and new Claims 34-36, 38, and 39 are supported by page 3, lines 18-31. New Claims 37 and 40 are supported by previously pending Claims